Data coverage
Beat AML 1.0 is a collaborative research program involving 11 academic medical centers who worked collectively to better understand drugs and drug combinations that should be prioritized for further development within clinical and/or molecular subsets of acute myeloid leukemia (AML) patients. Beat AML 1.0 provides the largest-to-date dataset on primary acute myeloid leukemia samples offering genomic, clinical, and drug response. This dataset contains open Clinical Supplement and RNA-Seq Gene Expression Quantification data. This dataset also contains controlled Whole Exome Sequencing (WXS) and RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, and RNA-Seq Splice Junction Quantification
Access & permitted use
Review the publisher’s documentation for availability, eligibility and permitted uses, including commercial analysis, model training and redistribution.
NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies
Need help sourcing data?
Tell us your required fields, population, geography and time period. We can review suitable sources and licensing options.
Request sourcing help